Free Newsletter
Lundbeck poaches CEO from Wyeth ranks
Wanted: CEO who can find a new "cash cow" to push a Danish drugmaker past impending patent expirations. Found: Ulf Wiinberg, lately of Wyeth, to take over Lundbeck. Soon to be ex-president of Wyeth's operations in Europe, the Middle East, African and Canada, Wiinberg also had been charged with strategic oversight of Wyeth's biopharma. Can Wiinberg deliver for Lundbeck? No doubt we'll soon see what he can do.
- read Lundbeck's release
- check out the brief at Money AM
- see the item at PharmaGossip
Related Articles:
Lundbeck CEO resigns early
Lundbeck chair exits as company seeks calm
Lundbeck turns in promising depression data
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: